Immunic (NASDAQ:IMUX) Downgraded to Sell at StockNews.com

StockNews.com cut shares of Immunic (NASDAQ:IMUX – Free Report) from a hold rating to a sell rating in a research note published on Saturday morning. Separately, Brookline Capital Management reaffirmed a buy rating and set a $10.00 target price on shares of Immunic in a research report on Friday, April 5th. View Our Latest Report […]

Related Keywords

Germany ,United States , ,Immunic Inc ,Innovis Asset Management ,Sweet Financial Partners ,Acadian Asset Management ,Sierra Summit Advisors ,Free Report ,Brookline Capital Management ,Get Free Report ,Asset Management ,Financial Partners ,Immunic Daily ,Immunic ,Nasdaq Imux ,Imux ,Medical ,Downgrade ,Stocknews Com ,